All research
2026-06-15 PubMed

Microbial Proteases Drive Endothelial Barrier Disruption and DIC in Sepsis Pathogenesis

Microbial proteases and endothelial barrier disruption in sepsis: A neglected nexus.

Background

Sepsis is a life-threatening condition characterized by a dysregulated host response to infection, remaining a leading cause of global mortality. While host inflammatory pathways are extensively studied, the critical contribution of bacterial proteases to sepsis pathogenesis is often overlooked. Current therapeutic strategies often fall short because they primarily target host responses, neglecting direct microbial virulence factors that severely compromise vascular integrity. Understanding these bacterial mechanisms, particularly their impact on the vascular endothelium and coagulation cascades, is crucial for developing more effective interventions.

Study Design

This review synthesizes existing mechanistic insights into how bacterial proteases contribute to sepsis pathogenesis. It examines experimental models used to study these proteases, discusses current diagnostic challenges, and explores emerging protease-targeted therapeutic strategies. The authors focused on key microbial proteases such as EspP, Protease IV, LasB, and SpeB, analyzing their direct effects on the vascular endothelium, glycocalyx, and coagulation pathways by summarizing findings from various preclinical studies.

Results

Microbial proteases act as potent virulence factors, directly targeting the vascular endothelium and disrupting its integrity. They achieve this by cleaving junctional proteins, degrading the protective glycocalyx, and inactivating crucial anticoagulant molecules. This combined structural and functional damage leads to profound endothelial barrier failure and subsequent vascular leakage. Furthermore, these proteases directly degrade key coagulation factors such as fibrinogen, factor V, factor VIII, and thrombin, significantly contributing to the progression toward disseminated intravascular coagulation (DIC). Beyond direct endothelial damage, bacterial proteases also exacerbate inflammation by increasing inflammatory cytokine release, degrading complement components, and driving overall thrombo-inflammatory dysregulation. Specific proteases like EspP, Protease IV, LasB, and SpeB have been identified as key players in these destructive processes. > These microbial proteases directly degrade critical coagulation factors, including fibrinogen, factor V, factor VIII, and thrombin, accelerating DIC progression in sepsis.

Key Findings

  • Bacterial proteases directly target and cleave endothelial junctional proteins, causing vascular barrier disruption.
  • Microbial proteases degrade the endothelial glycocalyx, further compromising vascular integrity in sepsis.
  • Key coagulation factors like fibrinogen, factor V, factor VIII, and thrombin are degraded by bacterial proteases.
  • Bacterial proteases inactivate anticoagulant molecules, promoting a procoagulant state and DIC.
  • Specific proteases (EspP, Protease IV, LasB, SpeB) are identified as major contributors to sepsis pathology.

Why It Matters

This review highlights a critical, often neglected, nexus in sepsis pathophysiology, emphasizing that targeting microbial proteases could offer novel therapeutic avenues. For clinicians and researchers, this shifts focus beyond host-centric inflammation to direct pathogen-mediated damage, suggesting that protease inhibitors or neutralizing antibodies could become valuable adjunctive therapies. This understanding could lead to new diagnostic biomarkers based on protease activity or specific protease detection. While still in early stages, identifying these mechanisms provides a strong rationale for developing protease-targeted interventions to protect the endothelium and prevent DIC, potentially improving patient outcomes significantly. This is not a usable protocol yet, but a foundational insight for future drug development.


sepsis microbial proteases endothelial dysfunction dic vascular leakage inflammation
Source: pubmed:42290137 · Ingested 2026-06-15 · Digest: gemini-2.5-flash